NEW YORK, Oct. 9, 2006 (PRIMEZONE) -- Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview(r) (EIO(r)) on Miami, Florida-based DOR BioPharma, Inc. (OTCBB:DORB). The full 48-page report can be found at www.crystalra.com and www.dorbiopharma.com.
DOR BioPharma, Inc. ("DOR" or "the Company") is a biopharmaceutical company addressing life-threatening side effects of cancer and cancer treatments, serious gastrointestinal diseases and disorders, and biodefense countermeasures. The Company's lead product, orBec(r) (oral beclomethasone dipropionate), is a potent, locally acting corticosteroid being developed to treat gastrointestinal Graft-versus-Host Disease (GI GVHD). GI GVHD is a rare disorder that can strike people whose immune system is suppressed after receiving allogeneic hematopoietic stem cell transplantation (HSCT), also known as bone marrow/stem cell transplantation, for cancer, as well as other gastrointestinal disorders characterized by severe inflammation. Symptoms of GI GVHD may include skin rash, intestinal problems similar to colitis, and liver dysfunction. The Company is also developing biodefense countermeasures pursuant to the paradigm established by the Project BioShield Act of 2004, which provides incentives for industry to expeditiously supply biodefense countermeasures to the Strategic National Stockpile (SNS). DOR's biodefense products in development are bioengineered vaccines to protect against the deadly effects of ricin toxin (with a vaccine called RiVax(tm) and botulinum toxin (with a vaccine called BT-VACC(tm)) -- both considered serious bioterrorism threats. The Company has headquarters in Miami, Florida.
About Crystal Research Associates, LLC
Crystal Research Associates, LLC is an independent research firm that provides institutional-quality fee-based research to small and mid-cap companies. The Company's unique and novel product, the Executive Informational Overview(r) (EIO(r)), is free of investment ratings, target prices, and forward-looking financial models. The EIO(r) presents a crystal-clear, detailed report on a company (whether public or private) in a manner that is easily understood by the Wall Street financial community. The EIO(r) details a company's product/technology/service offerings, market size(s), key intellectual property (IP), leadership, growth strategy, competition, risks, audited financial statements, key events and other such fundamental information. Crystal Research Associates has offices in New York City, Delray Beach, Montreal, and Toronto. Crystal Research Associates has been compensated by the Company $35,000 in cash and equity for its services in creating this report, for updates, and for printing costs. Included in this compensation: fifty-thousand (50,000) shares of DOR Common Stock and one-hundred and fifty thousand (150,000) Warrants.
Forward-Looking Safe Harbor Statement
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of the Company's technology, opportunities for the Company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of the Company's intellectual property, and economic conditions generally. Additional information on potential factors that could affect results and other risks and uncertainties are detailed from time to time in the Company's periodic reports, including Forms 10-KSB, 10-QSB, 8-K, and other forms filed with the Securities and Exchange Commission ("SEC") from time to time.
These statements, and other forward-looking statements, are not guarantees of future performance and involve risks and uncertainties. Crystal Research Associates, LLC assumes no obligation to update any of the forward looking statements in this release.